IMR Press / FBS / Volume 8 / Issue 2 / DOI: 10.2741/S465

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Role of mitochondria, ROS, and DNA damage in arsenic induced carcinogenesis

Show Less
1 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
2 Department of Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan
3 National Environmental Research Center, National Health Research Institutes, Zhunan, Taiwan
Academic Editors:Yau-Huei Wei, Myung-Shik Lee
Front. Biosci. (Schol Ed) 2016, 8(2), 312–320; https://doi.org/10.2741/S465
Published: 1 June 2016
Abstract

The International Agency for Research on Cancer (IARC) declared arsenic a class I carcinogen. Arsenic exposure induces several forms of human cancers, including cancers of skin, lung, liver, and urinary bladder. The majority of the arsenic-induced cancers occur in skin. Among these, the most common is Bowen’s disease, characterized by epidermal hyperplasia, full layer epidermal dysplasia, leading to intraepidermal carcinoma as well as apoptosis, and moderate dermal infiltrates, which require the participation of mitochondria. The exact mechanism underlying arsenic induced carcinogenesis remains unclear, although increased reactive oxidative stresses, leading to chromosome abnormalities and uncontrolled growth, and aberrant immune regulations might be involved. Here, we highlight how increased mitochondrial biogenesis and oxidative stress lead to mitochondrial DNA damage and mutation in arsenic induced cancers. We also provide therapeutic rationale for targeting mitochondria in the treatment of arsenic induced cancers.

Keywords
Arsenic
Mitochondria
ROS
DNA Damages
Carcinogenesis
Review
Share
Back to top